Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
RSS

Second-generation, highly selective COX-2 inhibitors developed at Merck

Nov. 18, 1997

SomatoKine shows potential for the treatment of osteoporosis

Nov. 18, 1997

Safety, immunogenicity and efficacy of anti-TNF antibody in RA patients

Nov. 18, 1997

Data presented on Shionogi's S-2150

Nov. 18, 1997

COX-2 antisense therapy for rheumatoid arthritis

Nov. 18, 1997

Improvement in early and established arthritis with antiangiogenic therapy

Nov. 18, 1997

Pharmacokinetic profile of ciclosporin derivative IMM-125

Nov. 18, 1997

Dainippon develops sustained-release morphine preparation

Nov. 18, 1997

Pharmacokinetic profile of Taisho's ACAT inhibitor

Nov. 18, 1997

New cardiotonic candidate studied, rejected at Fujisawa

Nov. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...